# EU-1-21-1598_public-assessment-report_20220117_20220117_sitagliptin-sun-epar-public-assessment-report.pdf

EUROPEAN MEDICINES AGENCY
SCIENCE
MEDICINES
HEALTH
14 October 2021
EMA/611380/2021
Committee for Medicinal Products for Human Use (CHMP)
Assessment report
Sitagliptin SUN
International non-proprietary name: sitagliptin fumarate
Procedure No. EMEA/H/C/005741/0000
Note
Assessment report as adopted by the CHMP with all information of a commercially confidential
nature deleted.
Official address Domenico Scarlattilaan 6 . 1083 HS Amsterdam . The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000
An agency of the European Union
C European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged.
Table of contents
1. Background information on the procedure
5
1.1. Submission of the dossier.
5
1.2. Legal basis, dossier content.
5
1.3. Information on paediatric requirements.
6
1.4. Information relating to orphan market exclusivity.
6
1.4.1. Similarity
6
1.5. Scientific advice
6
1.6. Steps taken for the assessment of the product
7
2. Scientific discussion
8
2.1. Introduction
8
2.2. Quality aspects
9
2.2.1. Introduction
9
2.2.2. Active substance
10
2.2.3. Finished medicinal product.
12
2.2.4. Discussion on chemical, and pharmaceutical aspects
16
2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects
16
2.2.6. Recommendations for future quality development.
16
2.3. Non-clinical aspects
16
2.3.1. Introduction
16
2.3.2. Ecotoxicity/environmental risk assessment
16
2.3.3. Discussion on non-clinical aspects
16
2.3.4. Conclusion on the non-clinical aspects
17
2.4. Clinical aspects
17
2.4.1. Introduction
17
2.4.2. Clinical pharmacology
18
2.4.3. Discussion on clinical aspects
21
2.4.4. Conclusions on clinical aspects
22
2.5. Risk Management Plan
22
2.5.1. Safety concerns
22
2.5.2. Pharmacovigilance plan
22
2.5.3. Risk minimisation measures.
22
2.5.4. Conclusion
23
2.6. Pharmacovigilance
23
2.6.1. Pharmacovigilance system
23
2.6.2. Periodic Safety Update Reports submission requirements
23
2.7. Product information
23
2.7.1. User consultation
23
3. Benefit-risk balance
23
4. Recommendations
24
Assessment report
EMA/611380/2021
Page 2/26
